Karyopharm to Report Second Quarter 2017 Financial Results on August 8, 2017
August 01 2017 - 6:00AM
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage
pharmaceutical company, announced today that it will report second
quarter 2017 financial results and provide a company update on
Tuesday, August 8, 2017. Karyopharm's management team will host a
conference call and audio webcast at 8:30 a.m. ET on Tuesday,
August 8, 2017 to discuss the financial results and recent business
developments.
To access the conference call, please
dial (855) 437-4406 (local) or (484) 756-4292
(international) at least 10 minutes prior to the start time and
refer to conference ID 53128722. A live audio webcast of the call
will be available under "Events & Presentations" in the
Investor section of the Company's
website, http://investors.karyopharm.com/events.cfm. An
archived webcast will be available on the Company's website
approximately two hours after the event.
About Karyopharm
Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a
clinical-stage pharmaceutical company focused on the discovery and
development of novel first-in-class drugs directed against nuclear
transport and related targets for the treatment of cancer and other
major diseases. Karyopharm's SINE™ compounds function by binding
with and inhibiting the nuclear export protein XPO1 (or
CRM1). The Company's initial focus is on seeking regulatory
approval and commercialization of its lead drug candidate, oral
selinexor (KPT-330). To date, over 2,100 patients have been
treated with selinexor and it is currently being evaluated in
several mid- and later-phase clinical trials across multiple cancer
indications, including in multiple myeloma in a pivotal, randomized
Phase 3 study in combination with Velcade® (bortezomib) and
low-dose dexamethasone (BOSTON), in combination with low-dose
dexamethasone (STORM) and backbone therapies (STOMP), and in
diffuse large B-cell lymphoma (SADAL), and liposarcoma (SEAL),
among others. Additional Phase 1, Phase 2 and Phase 3 studies are
ongoing or currently planned, including multiple studies in
combination with one or more approved therapies in a variety of
tumor types to further inform the Company's clinical development
priorities for selinexor. In addition to single-agent and
combination activity against a variety of human cancers, SINE™
compounds have also shown biological activity in models of
neurodegeneration, inflammation, autoimmune disease, certain
viruses and wound-healing. Karyopharm, which was founded by Dr.
Sharon Shacham, currently has five investigational programs in
clinical or preclinical development. For more information, please
visit www.karyopharm.com.
Velcade® is a registered trademark of Takeda
Pharmaceutical Company Limited.
Contacts:
Michelle Carroll
(212) 600-1902
michelle@argotpartners.com
Media:
Eliza Schleifstein
(917) 763-8106
eliza@argotpartners.com
Karyopharm Therapeutics (NASDAQ:KPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Karyopharm Therapeutics (NASDAQ:KPTI)
Historical Stock Chart
From May 2023 to May 2024